{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T07:02:40Z","timestamp":1779692560135,"version":"3.53.1"},"reference-count":24,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T00:00:00Z","timestamp":1779667200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To compare the efficacy and safety of immunotherapy combined with induction chemotherapy followed by radiotherapy alone or one cycle of concurrent chemoradiotherapy with cisplatin versus induction chemotherapy followed by two cycles of concurrent chemoradiotherapy with cisplatin in patients with locally advanced nasopharyngeal carcinoma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A total of 173 patients with locally advanced nasopharyngeal carcinoma treated at our hospital from November 2019 to September 2024 were retrospectively analyzed. Patients received induction therapy with immunotherapy (toripalimab or tislelizumab) combined with chemotherapy (TPC or GP) followed by radiotherapy alone or one cycle of concurrent chemoradiotherapy with cisplatin (immunochemotherapy group). Patients received TPC or GP induction chemotherapy followed by 2 cycles of concurrent chemoradiotherapy with cisplatin (IC-CCRT group). Immunotherapy was given on day 1 of each cycle of induction therapy. The efficacy and toxicities of the two groups were evaluated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>After induction therapy, 20 patients (29.4%) in the immunochemotherapy group and 15 patients (14.3%) in the IC-CCRT group achieved complete remission (p=0.02). At a median follow-up of 27.5 months, recurrence or metastasis occurred in 7.4%(5\/68) of the patients in the immunochemotherapy group and 19.0%(20\/105) of those in the IC-CCRT group. The 2-year event-free survival (EFS), overall survival (OS), locoregional recurrence-free survival (LRRFS) and distant metastasis-free survival (DMFS) in the immunochemotherapy group were 93.5% vs 81.1% (p=0.03), 100.0% vs 97.9% (p=0.3), 96.9% vs 91.4% (p=0.2), 95.0% vs 88.2% (p=0.1) compared with the IC-CCRT group. There were 28 cases (41.1%) in the immunochemotherapy group and 58 cases (55.2%) in the IC-CCRT group experienced grade 3\u20134 acute adverse events. In the immunochemotherapy group, 4 patients developed grade 3\u20134 immune-related adverse events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Compared with induction chemotherapy followed by two cycles of concurrent chemoradiotherapy with cisplatin, immunotherapy combined with induction chemotherapy followed by radiotherapy alone or one cycle of concurrent chemoradiotherapy with cisplatin may improve the EFS of patients with locally advanced nasopharyngeal carcinoma with low adverse events. However, this data requires prospective randomized controlled studies to be confirmed in the future.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1766797","type":"journal-article","created":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T06:04:32Z","timestamp":1779689072000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Immunotherapy plus induction chemotherapy followed by radiotherapy alone or one cycle of concurrent chemotherapy with cisplatin vs induction chemotherapy followed by two cycles of concurrent chemotherapy with cisplatin in locoregionally advanced nasopharyngeal carcinoma"],"prefix":"10.3389","volume":"17","author":[{"given":"Renba","family":"Liang","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College","place":["Shenzhen, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinxiao","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Shenzhen Luohu People\u2019s Hospital","place":["Shenzhen, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manyi","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College","place":["Shenzhen, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengming","family":"Lan","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College","place":["Shenzhen, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangmeng","family":"Fu","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College","place":["Shenzhen, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Lei","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College","place":["Shenzhen, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teng","family":"Zou","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College","place":["Shenzhen, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College","place":["Shenzhen, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College","place":["Shenzhen, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingzhi","family":"Luo","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College","place":["Shenzhen, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Jin","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College","place":["Shenzhen, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianghu","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College","place":["Shenzhen, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/0030-4220(93)90436-8","article-title":"Nasopharyngeal carcinoma","volume":"394","author":"Chen","year":"2019","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djr325","article-title":"Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410","volume":"103","author":"Curran","year":"2011","journal-title":"J Natl Cancer Inst"},{"key":"B3","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1016\/j.ccell.2025.01.014","article-title":"Nivolumab combined with induction chemotherapy and radiotherapy in nasopharyngeal carcinoma: A multicenter phase 2 PLATINUM trial","volume":"43","author":"Xu","year":"2025","journal-title":"Cancer Cell"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(24)00594-4","article-title":"Induction-concurrent chemoradiotherapy with or without sintilimab in patients with locoregionally advanced nasopharyngeal carcinoma in China (CONTINUUM): a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial","volume":"403","author":"Liu","year":"2024","journal-title":"Lancet"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2025.1132","article-title":"Adjuvant PD-1 blockade with camrelizumab for nasopharyngeal carcinoma: The DIPPER randomized clinical trial","volume":"333","author":"Liang","year":"2025","journal-title":"JAMA"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(24)00504-7","article-title":"Neoadjuvant and adjuvant toripalimab for locoregionally advanced nasopharyngeal carcinoma: a randomised, single-centre, double-blind, placebo-controlled, phase 2 trial","volume":"25","author":"Liu","year":"2024","journal-title":"Lancet Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2023.6552","article-title":"Induction chemotherapy followed by radiotherapy vs chemoradiotherapy in nasopharyngeal carcinoma: A randomized clinical trial","volume":"10","author":"Dai","year":"2024","journal-title":"JAMA Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2025.13205","article-title":"Toripalimab combination therapy without concurrent cisplatin for nasopharyngeal carcinoma: The DIAMOND randomized clinical trial","volume":"334","author":"Xu","year":"2025","journal-title":"JAMA"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1110281","article-title":"The short-term efficacy and safety of induction chemotherapy combined with PD-1 inhibitor or anti-EGFR in locoregionally advanced nasopharyngeal carcinoma","volume":"13","author":"Xiang","year":"2023","journal-title":"Front Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1200\/jco.1998.16.4.1310","article-title":"Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099","volume":"16","author":"Al-Sarraf","year":"1998","journal-title":"J Clin Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2008.18.1545","article-title":"Randomized phase II trial of concurrent cisplatin-radiotherapy with or without neoadjuvant docetaxel and cisplatin in advanced nasopharyngeal carcinoma","volume":"27","author":"Hui","year":"2009","journal-title":"J Clin Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(16)30410-7","article-title":"Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised controlled trial","volume":"17","author":"Sun","year":"2016","journal-title":"Lancet Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx770","article-title":"A randomized trial of induction docetaxel-cisplatin-5FU followed by concomitant cisplatin-RT versus concomitant cisplatin-RT in nasopharyngeal carcinoma (GORTEC 2006-02)","volume":"29","author":"Frikha","year":"2018","journal-title":"Ann Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy249","article-title":"Final results of a randomized phase III trial of induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in patients with stage IVA and IVB nasopharyngeal carcinoma-Taiwan Cooperative Oncology Group (TCOG) 1303 Study","volume":"29","author":"Hong","year":"2018","journal-title":"Ann Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(21)00075-9","article-title":"Induction chemotherapy with lobaplatin and fluorouracil versus cisplatin and fluorouracil followed by chemoradiotherapy in patients with stage III-IVB nasopharyngeal carcinoma: an open-label, non-inferiority, randomised, controlled, phase 3 trial","volume":"22","author":"Lv","year":"2021","journal-title":"Lancet Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1905287","article-title":"Gemcitabine and cisplatin induction chemotherapy in nasopharyngeal carcinoma","volume":"381","author":"Zhang","year":"2019","journal-title":"N Engl J Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.28418","article-title":"Epstein-Barr virus nuclear antigen 1 (EBNA1) protein induction of epithelial-mesenchymal transition in nasopharyngeal carcinoma cells","volume":"120","author":"Wang","year":"2014","journal-title":"Cancer"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djz044","article-title":"Current treatment landscape of nasopharyngeal carcinoma and potential trials evaluating the value of immunotherapy","volume":"111","author":"Le","year":"2019","journal-title":"J Natl Cancer Inst"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-025-03169-0","article-title":"Efficacy and safety of induction immunotherapy plus chemotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: a meta-analysis","volume":"133","author":"Wu","year":"2025","journal-title":"Br J Cancer"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2024.106867","article-title":"Incorporation of PD-1 blockade into induction chemotherapy improved tumor response in patients with locoregionally advanced nasopharyngeal carcinoma in a retrospective patient cohort","volume":"154","author":"Yao","year":"2024","journal-title":"Oral Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1080\/07853890.2025.2453091","article-title":"Chemoimmunotherapy as induction treatment in concurrent chemoradiotherapy for patients with nasopharyngeal carcinoma stage IVa","volume":"57","author":"Wu","year":"2025","journal-title":"Ann Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1415246","article-title":"Additional PD-1 inhibitor improves complete response to induction chemotherapy in locally advanced nasopharyngeal carcinoma","volume":"15","author":"Yu","year":"2024","journal-title":"Front Immunol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2024.102058","article-title":"Tislelizumab plus neoadjuvant chemotherapy and concurrent chemoradiotherapy versus neoadjuvant chemotherapy and concurrent chemoradiotherapy for locally advanced nasopharyngeal carcinoma: A retrospective study","volume":"48","author":"He","year":"2024","journal-title":"Transl Oncol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/s00262-024-03698-2","article-title":"The efficacy and safety of adding PD-1 blockade to induction chemotherapy and concurrent chemoradiotherapy (IC-CCRT) for locoregionally advanced nasopharyngeal carcinoma: an observational, propensity score-matched analysis","volume":"73","author":"Jin","year":"2024","journal-title":"Cancer Immunol Immunother"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1766797\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T06:04:33Z","timestamp":1779689073000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1766797\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,25]]},"references-count":24,"alternative-id":["10.3389\/fimmu.2026.1766797"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1766797","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,25]]},"article-number":"1766797"}}